Trinity Biotech was founded in 1992 and listed on the NASDAQ market shortly after its formation. Through a combination of sustained, organic growth and an acquisition-led strategy, the company has assembled an impressive product portfolio and achieved the highest standards of excellence in developing, manufacturing and marketing diagnostic products.
Today Trinity Biotech is listed on the NASDAQ Global Select Market, and has approximately 21 million American Depository Shares.
The Company, which has its headquarters in Bray, Ireland, employs in excess of 350 people worldwide and markets its portfolio of over 400 products to customers in over 75 countries around the world.
Trinity Biotech’s growth to date has involved the following:
1994
March
Acquired Disease Detection International, Irvine, California, USA.
1996
July
Launched Uni-Gold™ HIV and One-step test.
1997
February
Acquired Clark Laboratories, Jamestown, New York, USA.
Acquired Centocor, Cambridge, UK.
1998
Opened 50,000 sq. ft. manufacturing facility in Bray, Ireland.
June
Acquired Hormone & Drugs of Abuse from Diatech, Boston, USA.
Acquired Macra® Lp(a) from Strategic Diagnostics Inc., USA.
September
Acquired HIV product line from Cambridge Diagnostics, USA.
October
Acquired MicroTrak® product line from Dade Behring, USA.
2000
Acquired MarDx® Diagnostics, Inc., Carlsbad, California, USA.
December
Acquired assets and goodwill of Bartels Inc., Oregon, USA.
2001
Establishment of Trinity Biotech German sales and marketing subsidiary
Acquired Biopool, Ventura, California, USA.
2002
August
Acquired coagulation division of Sigma Diagnostics, USA.
Establishment of Trinity Biotech UK sales & marketing subsidiary.
Acquired Specialty Clinical Chemistry, Sigma Diagnostics, USA.
2003
FDA clearance for Uni-Gold™ Recombigen® HIV test.
2004
April
Acquired Adaltis US, Inc.
Acquires Fitzgerald Industries International, Mass, USA.
November
Received US CLIA Waiver for Uni-Gold™ Recombigen® HIV Test.
2005
Acquired Research Diagnostics Inc., Flanders, New Jersey, USA.
Acquired Primus Corporation of Kansas City, Missouri, USA.
2006
Acquired coagulation division of bioMerieux, Lyon, France.
2010
May
Acquisition by Stago of the Trinity Biotech coagulation division.
2011
January